Burcon Nutrascience Corp - BRCNF STOCK NEWS

Burcon NutraScience (TSX: BU) (OTCQB: BRCNF) announces that its alliance partner, RE ProMan, , has completed the acquisition of a protein production facility in Galesburg, Illinois. The facility was chosen for its strategic location near agricultural growers and key transportation routes, as well as its existing processing capabilities that align with Burcon's protein technology platform.

The company plans to integrate its proprietary technologies into the facility and expects to begin commercial-scale production of protein products during the first half of 2025. This acquisition represents Burcon's first operational control of a commercial facility, positioning the company to deliver sustainable plant-based protein solutions to meet market demand.

Burcon NutraScience has successfully completed a rights offering, raising $9.43 million through the issuance of 110,986,126 common shares at $0.085 per share. The offering received strong support from strategic investors, including management and board members.

A total of 77,198,140 shares were issued under basic subscription rights, with 19,061,806 shares going to insiders and 58,136,334 to other investors. Additional subscription privileges resulted in 33,787,986 shares being issued. Following the offering, Burcon has 253,761,444 common shares outstanding.

The Insider Group now owns 30.64% of outstanding shares. The proceeds will primarily fund Burcon's obligations under a recently announced Manufacturing Agreement with RE ProMan, , and support the commercialization and scaling of protein products.

Burcon NutraScience (TSX: BU) (OTCQB: BRCNF) reported its fiscal 2025 Q3 results, marking a transformative period with several key developments. The company formed an alliance with ProMan to acquire and operate a protein production facility, which is in final due diligence phase. Burcon generated $62,000 in revenues and reported a net loss of $1.8 million ($0.01 per share), compared to $2.0 million loss in the same period last year.

The company successfully closed a rights offering raising $9.43 million, exceeding their $7 million target for production, marketing, and sales initiatives. Burcon launched new products including next-generation Peazazz® pea protein, Puratein® canola protein, and Solatein™ sunflower protein isolate. The company has over 100 customers evaluating their proteins and expects to begin commercial scale production in the first half of 2025.

Burcon NutraScience has successfully completed its rights offering, raising approximately $9.43 million through the issuance of 110,986,126 Common shares at $0.085 per share. The Rights Offering, which expired on February 12, 2025, exceeded the company's target of $7 million needed to execute its production plan and achieve positive cash flow by calendar 2026.

The company, a global technology leader in plant-based protein development, is currently working with its transfer agent to calculate the amounts exercised under the basic subscription privilege and additional subscription privilege. Further details, including information required by National Instrument 45-106, will be provided once available.

Burcon has registered the offer and sale of shares on a Form F-7 registration statement under the U.S. Securities Act of 1933. The company has also scheduled a virtual investor presentation for February 18, 2025, at 5:00 p.m. Eastern time.

Burcon NutraScience (TSX: BU) (OTCQB: BRCNF), a leader in plant-based protein technology, has announced a virtual Investor Presentation scheduled for February 18, 2025, at 5:00 p.m. Eastern time. The presentation will be led by CEO Kip Underwood to discuss recent company milestones.

The event will cover key topics including: the company's route to market through facility acquisition by alliance partner Re ProMan , plans to bring their entire protein portfolio to market with full operational control, details about their Rights Offering, and future plans. A live Q&A session will follow the presentation.

Investors can participate through a webcast available on Burcon's website under 'Presentations' or join via phone using toll-free number 1-800-717-1738 (North America) or 1-646-307-1865 (International) with Conference ID: 37581. Questions can be submitted in advance to plam@burcon.ca.

Burcon NutraScience (TSX: BU) (OTCQB: BRCNF) has entered into an agreement with RE ProMan, for a protein production facility in North America. The deal includes a seven-year manufacturing agreement followed by a ten-year lease arrangement. Under the terms, ProMan will purchase the facility and grant Burcon exclusive access to 100% of manufacturing capacity for its plant protein portfolio.

The agreement includes an annual production fee with a fixed portion totaling US$19.8 million over seven years, plus variable costs. First-year sales are projected at $1-3 million, with double-digit revenue expected in year two. Gross margins are targeted to exceed 50% as capacity utilization increases, with profitability and positive cash flow anticipated in 2026.

Due to ProMan being controlled by Burcon director John Vassallo, the agreement requires disinterested shareholder approval. The deal is conditional on Burcon receiving regulatory approvals, ProMan completing the facility acquisition by April 30, 2025, and Burcon securing minimum financing of CAD$7 million.

Burcon NutraScience (TSX: BU) (OTCQB: BRCNF) announced that its alliance partner, RE ProMan, , has signed a Purchase and Sale Agreement to acquire a protein production facility in North America. The agreement was signed by ProMan, led by John Vassallo, who is also a director and shareholder of Burcon.

The acquisition is subject to due diligence and approval by the parties. The facility was selected after reviewing several commercial locations capable of producing Burcon's entire protein portfolio. Burcon has prepared comprehensive plans for facility start-up, including raw material procurement, production ramp, and product launch.

Upon transaction closing, Burcon plans to install proprietary unit operations and begin commercial-scale production of its protein products during the first half of 2025. This acquisition will provide Burcon with direct market access for all its protein products and control over commercial production.

Burcon NutraScience (TSX: BU) (OTCQB: BRCNF) has launched Solatein™, a groundbreaking high-purity sunflower protein isolate. The product features over 90% protein purity and is designed to meet growing consumer demand for protein supplements, particularly among GLP-1 weight management medication users.

Solatein™ offers unique characteristics including neutral flavor, off-white color, and exceptional functionality for food and beverage applications. The non-GMO, hypoallergenic protein is rich in sulfur-containing amino acids and is produced through an innovative process that upcycles sunflower seed oil production by-products.

According to Goldman Sachs Research, GLP-1 medication users are expected to increase significantly over the next five years, creating new opportunities in the protein supplement market. Burcon's expanded portfolio aims to address this growing demand with its highly differentiated plant-based protein solutions.

Burcon NutraScience (TSX: BU) (OTCQB: BRCNF) has provided an update on its previously announced rights offering. The company has secured registration requirement exemptions in Arizona, Arkansas, Minnesota, and Wisconsin, allowing shareholders in these states to participate in the offering.

Each shareholder of record as of November 27, 2024, will receive one transferable right for each common share held, enabling them to purchase one common share at $0.085. The rights are trading on TSX under 'BU.RT' until February 12, 2025. Shareholders must complete a subscription form and submit payment by 5:00 p.m. Eastern time on that date.

Ineligible shareholders outside eligible jurisdictions must complete an Exempt Purchaser Status Certificate by February 5, 2025, to participate.